文献速递免疫规划传染病防控与疫情报告

COVID-19疫苗反应原性——荷兰基于患者报告结局的队列事件监测研究

COVID-19 vaccine reactogenicity - A cohort event monitoring study in the Netherlands using patient reported outcomes.
PubMed 文献 · Vaccine · 2022-01-17

该研究采用基于网络的前瞻性队列设计,纳入荷兰COVID-19免疫规划中22184名受试者,使用患者报告结局探索首剂接种后反应原性的相关因素。结果显示,与Comirnaty®疫苗相比,Vaxzevria®疫苗发生反应原性的比值比最高(OR 5.18),其次为Spikevax®(OR 2.16)和Janssen(OR 1.65);有COVID-19病史者、女性及年轻者发生反应原性的比值比升高。

要点

  • 与Comirnaty®相比,Vaxzevria®发生反应原性的OR为5.18,Spikevax®为2.16,Janssen为1.65。
  • 有COVID-19病史者发生反应原性的OR为3.10,女性较男性OR为2.08。
  • 与<50岁组相比,50-60岁、61-79岁和≥80岁组发生反应原性的OR分别为0.36、0.15和0.10。

核心结论

  • 在荷兰超过22000名疫苗受种者中,综合考虑模型中的所有因素,首剂接种后Comirnaty®疫苗的反应原性(总体和全身性)最低,Vaxzevria®疫苗最高。
  • 有COVID-19病史、女性及较年轻者接种后发生反应原性的比值比升高。

研究设计与样本

  • 基于网络的前瞻性队列设计,使用患者报告结局。
  • 研究人群为在荷兰COVID-19免疫规划中接种任何品牌COVID-19疫苗者,共22184名参与者。
  • 其中13959名(62.9%)在接种后7天内出现总体反应原性,11979名(54.0%)出现全身性反应原性。

主要发现

  • 与Comirnaty®疫苗相比,发生反应原性的比值比最高为Vaxzevria®疫苗(OR 5.18),其次为Spikevax®(OR 2.16)和Janssen(OR 1.65)。
  • 有COVID-19病史的参与者发生反应原性的比值比为3.10;女性较男性OR为2.08。
  • 与<50岁年龄组相比,50-60岁、61-79岁和≥80岁组发生反应原性的OR分别为0.36、0.15和0.10。
  • 使用退热药或神经系统疾病药物者发生反应原性的OR分别为1.34和1.16;体重指数25.0-29.9和超过30与反应原性呈负相关(OR分别为0.87和0.72)。
  • 与反应原性相关的合并症包括心脏疾病(OR 1.26)、呼吸系统疾病(OR 1.31)、精神疾病(OR 1.37)、生殖系统疾病(OR 1.54)和眼部疾病(OR 1.55)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To explore factors that are associated with reactogenicity in general and systemic after the first dose of COVID-19 vaccine in the Netherlands. DESIGN: A web-based prospective cohort design using patient reported outcomes (PROs). SETTING: Any person who has been vaccinated with any brand of COVID-19 vaccine in the Dutch COVID immunization programme. PARTICIPANTS: 22,184 participants. Of these, 13,959 (62.9%) experienced reactogenicity in general and 11,979 (54.0%) systemic reactogenicity within 7 days after vaccination. MAIN OUTCOME MEASURES: Factors that are associated with the occurrence of reactogenicity after COVID-19 vaccination. RESULTS: Compared to the Comirnaty® vaccine, the highest odds ratio (OR) for developing reactogenicity was for the Vaxzevria® vaccine (OR 5.18) followed by Spikevax® (OR 2.16), and Janssen (OR 1.65). Participants with a history of COVID-19 disease had a 3.10 increased odds for reactogenicity. Women had a 2.08 increased odds compared to men. Older participants experienced less reactogenicity. Compared to the age group < 50, the ORs for the age groups 50-60, 61-79, and ≥80 were 0.36, 0.15, and 0.10 respectively. The use of an antipyretic drug, or a drug for nervous system disorders gave an increased odds of 1.34 and 1.16 respectively. A body mass index of 25.0-29.9 and over 30 was negatively associated with reactogenicity (OR 0.87 and OR 0.72 respectively). Comorbidities that were associated with reactogenicity were cardiac disorders (OR 1.26), respiratory disorders (OR 1.31), psychiatric disorders (1.37), reproductive disorders (OR 1.54), and eye disorders (OR 1.55). The factors associated with systemic reactogenicity were mostly comparable, but there were differences for comorbidities, drug use, and the strength of the regression coefficient. CONCLUSIONS: This extensive study with over 22,000 vaccine recipients in the Netherlands demonstrated that, taken into account all factors in the model, the Comirnaty® vaccine gave the least and the Vaxzevria® vaccine the most reactogenicity in general and systemic after the first dose. Also a person with a history of COVID-19 disease, female sex and younger age had an increased odds for experiencing reactogenicity after vaccination.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Rolfes L, Härmark L, Kant A, et al. COVID-19 vaccine reactogenicity - A cohort event monitoring study in the Netherlands using patient reported outcomes. Vaccine. 2022. PMID: 35067381. doi:10.1016/j.vaccine.2022.01.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。